


THROMBOTECT - a randomized controlled trial comparing three regimens for thromboprophylaxis during induction chemotherapy of acute lymphoblastic leukemia in children and adolescents



1 Leukemia in children
 2 Chemotherapy (including asparaginase)
 3 Central venous catheter


↓

Risk of thromboembolic events (TE)

- 949 Children (age 1 to 18 years) with acute lymphoblastic leukemia
- 312 Low-dose Unfractionated Heparin (UFH)
- 317 Prophylactic-dose Low Molecular Weight Heparin (LMWH)
- 320 Activity-adapted Antithrombin substitution (AT)

	Risk of TE	Rejection of treatment	5-year-event free survival
UFH	8.0%	3%	85.9±2.0%
LMWH	3.5% (P=0.011)	33%	86.2±2.0%
AT	1.9% (P<0.001%)	3%	80.9±2.2%

Intention-to-treat analysis



Prophylactic use of antithrombin or low molecular weight heparin significantly reduced thromboembolism